Reports of hematopoietic stem-cell transplantation (HSCT) following solid-organ transplantation have been described in adults mainly as case reports. These reports demonstrate feasibility but likely do not reflect true outcomes due to a positive reporting bias. We report herein the outcomes of all our pediatric recipients of allogeneic HSCT following previous solid-organ transplantation between 2000 and 2009. Four children were identified. Two patients underwent heart transplantation followed by cord-blood allogeneic HSCT for T-cell lymphoma/post transplant lymphoproliferative disease (PTLD) and two patients underwent liver transplantation followed by living-donor allogeneic HSCT for severe aplastic anemia (SAA). The mean time between transplants was 4.2 years (range 1.5-6 years). All patients engrafted; however, all patients died from 37 days to 1 year after HSCT. Causes of death included infections (n ¼ 2), multi-organ failure (n ¼ 1) and solid-organ graft rejection (n ¼ 1). Though three patients survived beyond day þ 100, multiple complications were observed including EBV re-activation followed by EBV-positive PTLD (n ¼ 1) and five episodes of severe infections. The patients transplanted for lymphoma did not have evidence of recurrence at last follow-up. Although feasibilty has been shown with this cohort, we conclude that allogeneic HSCT in immunosuppressed patients following solid-organ transplantation remains a very high risk procedure that results in severe morbidity and mortality in children.
Introduction
There are minimal data on sequential hematopoietic stem-cell transplantation (HSCT) following solid-organ transplantation in the literature and most information comes from case reports of successful transplantation. [1] [2] [3] [4] [5] [6] However, those publications likely reflect a positive reporting bias, as no reports of a cohort have been published to date. The need for complete cohort studies or prospective studies of such transplants is essential for clinicians to be able to understand appropriate indications, complications and outcomes. Indications for HSCT after solid-organ transplantation that have been reported include mainly severe aplastic anemia (SAA) following liver transplantation. [2] [3] [4] [5] [6] Post transplant lymphoproliferative disease (PTLD) is an important cause of morbidity and mortality after solid-organ or stem-cell transplantation, with a reported incidence of 1-10% in all adult transplant recipients; this number has been reported to be even higher in children. [7] [8] [9] [10] [11] [12] [13] PTLD represents a spectrum of lymphoid proliferation that can progress to monoclonal malignant lymphoma. 14, 15 Treatment failure in malignant PTLD/lymphoma is high and in particular there are limited treatment options for T-cell PTLD/lymphoma. The challenge of undertaking HSCT for the treatment of PTLD/lymphoma in previously transplanted patients is significant. Allogeneic HSCT postcardiac transplantation to treat PTLD/lymphoma has neither been previously published nor has the use of cord blood as a source for stem cells in this population.
In this study, we present the outcomes of a cohort of pediatric patients who underwent allogeneic HSCT following solid-organ transplantation over the last decade at our institution. Our objectives were to describe the indications for HSCT, the patients' characteristics and course post transplant, as well as survival outcomes. We also sought to discuss the utilization of cord-blood stem cells as a potential source, as well as the indication of HSCT for PTLD/lymphoma. 
Patients and methods

Data collection
The following variables were collected: gender, age, indication for solid-organ transplant, type of organ utilized (living/orthotopic), immunosuppressive regimen and post transplantation clinical course. The indication for allogeneic HSCT, type of preparative regimen (myeloablative vs reduced intensity), 16 donor type and degree of matching, GVHD prophylaxis and therapy if GVHD occurs were also reported. Donor selection for patients' post-cardiac transplantation aimed for blood group compatibility between the donor cells and the transplanted heart.
Following stem-cell infusion, all patients were isolated and nursed in laminar airflow rooms until neutrophil recovery (ANC 40.5 Â 10 9 /L). Neutrophil engraftment was defined as the first of three consecutive days of ANC 40.5 Â 10 9 /L. Infection prophylaxis included: fluconazole for fungal prophylaxis, intravenous immunoglobulin for IgG levels o5 g/L or weekly if the recipient or donor was CMV IgG positive by pre-HSCT serology. Pneumocystis jiroveci pneumonia prophylaxis was given for at least 6 months post-HSCT or longer if patients were still on immunosuppressive therapy and pneumococcal prophylaxis with penicillin was given for at least 1 year post-HSCT or until the administration of pneumococcal vaccine.
Non-relapse mortality was defined as any death after transplant that occurred without evidence of recurrent/new malignancy.
Results
HSCT for PTLD post-heart transplantation Two cases of HCST for PTLD post transplantation were identified in our series (patients' characteristics and HSCT data are summarized in Table 1 ). Both a 21-monthold girl with prior heart transplantation at the age of 3 months due to ischemic cardiomyopathy and an 8-yearold boy who underwent heart transplantation for hypoplastic left heart syndrome presented with mature T-cell PTLD/lymphoma. Both patients were receiving tacrolimusbased immunosuppression when the lymphoma was diagnosed. The lymphomas of both patients showed clonal T-cell receptor Vb re-arrangements. EBV studies were negative.
Patient 1 had stage IV disease with bone-marrow involvement. Due to bone-marrow involvement at diagnosis as well as failure to respond to front line protocols, an allogeneic HSCT was offered. Echocardiogram done before HSCT was normal with good biventricular systolic function. The cord stem-cell source was an HLA match at four of six loci with an HLA-B antigenic and an HLA-DRB1 allelic mismatch. The donor stem cells were ABO matched to the transplanted heart. The conditioning regimen is presented in Table 1 . GVHD prophylaxis included methyl- Outcomes of sequential bone marrow and solid-organ transplants T Schechter et al prednisolone (2 mg/kg/day) and tacrolimus. Complications of post transplant are summarized in Table 1 . Routine echocardiogram during hospitalization for HSCT revealed good biventricular function, with an ejection fraction ranging between 71 and 77%. Neutrophil recovery to 0.5 Â 10 9 /L was observed at day þ 43. Engraftment studies by FISH testing of a peripheral blood sample demonstrated full donor chimerism. She underwent re-evaluation of the PTLD at 1 year post-HSCT that showed no evidence of disease by positron emission tomography-computed tomography (PET-CT), as well as absence of the malignant clone in the peripheral blood. After documenting full donor chimerism, the patient was treated with tacrolimus only targeting levels between 3-5 mcg/L to prevent cardiac rejection, but developed severe humoral heart rejection with arrythmia and died at 1 year post-HSCT.
Patient 2 had stage III disease. Due to a poor response to the various treatment regimens, an allogeneic HSCT was offered. Similar to patient one, the cord stem-cell source was an HLA match at four of six loci with an HLA-B antigenic mismatch and an HLA-DRB1 allelic mismatch. A mismatch between cord-blood group and the transplanted heart was the only stem-cell source found for this patient. The conditioning regimen is presented in Table 1 . An echocardiogram done before HSCT was normal with good biventricular systolic function. GVHD prophylaxis included methylprednisolone (2 mg/kg/day) and tacrolimus. Neutrophil recovery occurred on day þ 32 with full donor chimerism documented by FISH testing. On day þ 34 following diffuse lymphadenopathy he was diagnosed with EBV-positive monomorphic large B-cell PTLD (CD 20 þ , CD22 þ and CD79 þ ) and was treated with six doses of rituximab with good response. After the first month post-HSCT, immunosuppression was switched from tacrolimus to sirolimus. New lung nodules were treated with voriconazole with resolution of the lung findings. At 6 months after HSCT, he was admitted for HSV re-activation and developed influenza A pneumonia; after recovery, he subsequently developed Pneumocystis jiroveci pneumonia and his bronchoalveolar lavage was positive as well for adenovirus. His respiratory status deteriorated and despite conventional ventilation and then extra corporeal membrane oxygenation (ECMO), he succumbed to severe intracranial hemorrhage and respiratory failure. No evidence of PTLD or humoral rejection due to blood group mismatch between the cord given and the transplanted heart was documented at last evaluation.
HSCT for SAA post-liver transplantation Patient 3: A 14-year-old girl with prior orthotopic liver transplantation at the age of 8 years for fulminant non-typable hepatitis, presented with SAA, while on immunosuppression with cyclosporine A. After liver transplantation she developed aortitis, myositis and intracranial hemorrhage. She was diagnosed with SAA followed by monosomy 7 at 5 years after liver transplantation. No related or unrelated suitably HLA matched donor could be found and the only available donor was haploidentical. She underwent HSCT 6 years after the liver transplantation. The conditioning regimen is presented in Table 1 . The patient had neutrophil engraftment at 12 days post-HSCT. Liver-related complications after HSCT included the development of veno-occlusive disease followed by severe gastrointestinal hemorrhage. Liver biopsy was positive for adenovirus 3 months after HSCT and she was treated with ribavirin and gancyclovir. Other complications after HSCT were Streptococcus viridans sepsis, disseminated adenovirus infection and transient ischemic attacks. The patient died 6 months post-HSCT from heart failure, massive gastrointestinal bleed and disseminated adenovirus infection.
Patient 4: An 11-year-old boy underwent orthotopic liver transplantation at the age of 9 years for fulminant nontypable hepatitis and presented with SAA 2 years later. He developed PTLD 6 months post-liver transplantation, as well as renal impairment. Immunosuppression before HSCT included antithymocyte globulin, cyclosporine A and prednisone. This patient underwent allogeneic HSCT from a living unrelated donor (10/10 HLA match). The conditioning regimen is presented in Table 1 . The patient had neutrophil engraftment at 15 days post-HSCT. Liverrelated complications after HSCT included the development of significantly elevated bilirubin and liver transaminases. Liver biopsy was negative for GVHD or liver rejection. Following the liver injury, the patient developed progressive multi-organ failure and died and 37 days after HSCT. No infectious etiology was found.
Discussion
As the use of solid-organ transplantation has become standard of care therapy in the pediatric population for end stage organ failure, new indications for allogeneic HSCT have emerged and with them the need to fully understand the risks and benefits of allogeneic HSCT following solidorgan transplantation.
The role of HSCT for hematologic malignancies after solid-organ transplantation is unclear. Reports of such interventions are published as case reports and use mainly living-related donors. 17 Chiang et al. reviewed the outcome of four patients with leukemia/myelodysplastic syndrome (MDS) who received HSCT from living-related donors. Two patients survived at a follow-up of 7-22 months after receiving myeloablative conditioning regimen. Kobbe et al. 18 reported successful use of non-myeloablative conditioning regimen followed by matching-related HSCT for a patient with MDS following heart transplantation. The use of allogeneic HSCT for PTLD has not been previously described
The development of PTLD is a risk after solid-organ transplant and HSCT, with a reported incidence in pediatric patients of up to 10% after solid-organ transplant. 7, 13 EBV naive children at the time of transplant have been shown to have a higher risk than adults. T-cell lineage PTLD/lymphoma is a rare subtype of PTLD, comprising up to 14% of all PTLD cases and is usually of peripheral (post-thymic) T-cell subtype. 1, 15, 19 Disseminated peripheral T-cell lymphomas are a therapeutic challenge as they behave aggressively and only a minority of cases responds to chemotherapy, even in the non-immunocompromised patient. 20 The 1-year survival is reported to be between 30 and 50% and is worse for T-PTLD with 11 of 14 reported pediatric T-cell PTLD/lymphoma patients having died of disease. 20, 21, 22 Only one instance of successful treatment of pediatric T-cell PTLD/lymphoma has been described in the literature. In that case due to the refractory nature of the lymphoma, consolidation therapy with autologous HSCT was performed. 23 Our two patients also presented with late onset mature T-cell lymphoma/PTLD, non-EBV associated. One patient had a poor primary response and the other had at presentation bone-marrow involvement of the disease. Hence, we elected to offer consolidation therapy with allogeneic HSCT for both patients. The role of allogeneic HSCT for stage IV T-cell lymphoma outside the context of PTLD shows encouraging results with an overall survival up to 40%, but a high risk non-relapse mortality of up to 39%. 24 For the patient younger than 3 years, we elected to use a conditioning regimen reported for transplant of children with acute lymphoblastic leukemia that showed similar results to a TBI approach, in an attempt to avoid TBI side effects. 25 For the second patient, we used the combination of cyclophosphamide and TBI. Mismatched cord blood stem cells were the only available options in both patients in the time frame available to us and both the patients engrafted those stem cells.
HSCT post-heart transplantation is a challenging clinical situation with only two cases previously reported in the literature. 1, 26 Neither case was for PTLD therapy or used cord blood as a stem-cell source. One case report described successful HSCT post-heart transplantation in 2005 in an adult with amyloidosis. 26 HSCT was performed 6 months after heart transplantation using hematopoietic stem cells from an unrelated donor. The conditioning regimen included busulfan and cyclophosphamide, and GVHD prophylaxis included tacrolimus, mycophenolate mofetil (MMF) and methylprednisolone. This patient was also given antithymocyte globulin to prevent cardiac rejection. Follow-up post-HSCT was satisfactory without any signs of GVHD, infection or cardiac rejection assessed by endomyocardial biopsies. 26 The only case report of pediatric sequential heart and HSCT was reported recently by Mangat et al. 1 They reported a 7.5-year-old child who underwent heart transplantation for anthracycline induced cardiomyopathy. Subsequently, the child relapsed with his primary disease and HSCT (matched sibling donor) was performed 2 months after heart transplant. The conditioning regimen was tolerated well and included busulfan and cyclophosphamide. The only reported complication was mild GVHD, which responded to therapy. His cardiac function 2 years from HSCT remained good with a shortening fraction of 35%. This is in contrast to our patients, who did not survive and succumbed to infectionrelated non-relapse mortality and graft rejection.
The second pair of patients in our cohort underwent HSCT for SAA. SAA is a well-reported and common complication of liver transplantation for non-A, non-B, non-C hepatitis with reports of mortality rates as high as 40-50% during courses of immunosuppressive therapy, primarily due to infectious complications. 27, 28 HSCT for SAA has been reported following liver and kidney transplantation. 29 However, successful allogeneic HSCT in pediatric patients developing SAA following orthotopic liver transplantation has been previously described only in case reports. [2] [3] [4] [5] [6] 30 All the reported HSCT utilized matched living-related donors. The case reports had very short follow-up and no reported complications. 6 In the case report with the longest follow-up, the patient had severe complications following HSCT with development of metastatic renal cell carcinoma and a mucoepidermoid carcinoma of the parotid gland both of which were treated surgically. 5 The stem-cell donors for our patients were different from these previous reports with one patient receiving a 10 out of 10 HLA matched living-unrelated donor and the other a haploidentical donor. Both of the patients engrafted, but succumbed to multi-organ failure and infections at 1 and 6 months post-HSCT. One patient developed evidence of liver injury that was, however, negative on a biopsy for GVHD or rejection.
While this is the largest reported series to date, our study is, nonetheless, limited by the small number of patients and its observational nature and we were unable to analyze the association between other potentially significant factors and survival outcome. The outcome of the patients in this series demonstrates the increased risk of severe opportunistic infections in these chronically immunosuppressed patients as well as the risk of solid-organ rejection at the time of immune system recovery. Despite the feasibility of doing the combined procedures, for patients with malignancies our data may encourage clinicians to explore other treatment options before considering HSCT. For patients with SAA, when no matching related donor exists, the risk benefit ratio of alternative donor HSCT needs to be carefully considered.
